Cantor Fitzgerald Predicts Lower Earnings for Alector

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share estimate for Alector down to ($1.53), compared to a prior estimate of ($1.45), while the consensus estimate stands at ($1.88).
• Alector's recent earnings report showed a loss of ($0.30) per share for the quarter, beating expectations, with revenues of $7.87 million against an estimate of $2.76 million.
• Institutional investors hold a significant stake in Alector, owning 85.83% of the company, and several have recently increased their positions significantly.

Alector, Inc. (NASDAQ:ALEC - Free Report) - Investment analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of Alector in a research report issued on Wednesday, October 1st. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings per share of ($1.53) for the year, down from their previous forecast of ($1.45). The consensus estimate for Alector's current full-year earnings is ($1.88) per share. Cantor Fitzgerald also issued estimates for Alector's FY2026 earnings at ($1.43) EPS.

Alector (NASDAQ:ALEC - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.15. The company had revenue of $7.87 million for the quarter, compared to analyst estimates of $2.76 million. Alector had a negative net margin of 142.10% and a negative return on equity of 112.06%. Alector has set its FY 2025 guidance at EPS.

Several other research firms have also issued reports on ALEC. Wall Street Zen lowered shares of Alector from a "hold" rating to a "sell" rating in a research report on Friday, September 26th. Mizuho raised shares of Alector from a "neutral" rating to an "outperform" rating and boosted their target price for the company from $2.50 to $3.50 in a report on Monday, July 28th. Finally, BTIG Research reaffirmed a "buy" rating and issued a $5.00 price target on shares of Alector in a report on Thursday, September 25th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Alector presently has an average rating of "Hold" and an average price target of $4.17.

Alector Stock Performance

NASDAQ:ALEC opened at $3.16 on Friday. The company has a market capitalization of $319.82 million, a P/E ratio of -2.72 and a beta of 0.99. The business has a fifty day simple moving average of $2.44 and a two-hundred day simple moving average of $1.70. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.78 and a quick ratio of 3.78. Alector has a 1 year low of $0.87 and a 1 year high of $6.14.

Institutional Investors Weigh In On Alector

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC increased its position in shares of Alector by 50.7% during the second quarter. Acadian Asset Management LLC now owns 2,170,388 shares of the company's stock worth $3,033,000 after purchasing an additional 729,727 shares in the last quarter. TD Asset Management Inc lifted its stake in Alector by 483.3% in the 2nd quarter. TD Asset Management Inc now owns 651,738 shares of the company's stock worth $912,000 after purchasing an additional 540,000 shares in the last quarter. Vestal Point Capital LP acquired a new position in shares of Alector during the 1st quarter worth approximately $621,000. Jacobs Levy Equity Management Inc. grew its position in shares of Alector by 25.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,334,032 shares of the company's stock valued at $1,641,000 after purchasing an additional 274,341 shares in the last quarter. Finally, State of Wyoming acquired a new stake in shares of Alector in the first quarter valued at approximately $242,000. Hedge funds and other institutional investors own 85.83% of the company's stock.

Insider Buying and Selling at Alector

In related news, Director Paula Hammond sold 14,000 shares of the company's stock in a transaction on Tuesday, August 26th. The stock was sold at an average price of $2.36, for a total value of $33,040.00. Following the sale, the director directly owned 74,909 shares of the company's stock, valued at $176,785.24. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 9.70% of the company's stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.